• Target：
• PIK3CA H1047R

• Fields：
• >>Inositol phosphate metabolism;>>Metabolic pathways;>>EGFR tyrosine kinase inhibitor resistance;>>Endocrine resistance;>>Platinum drug resistance;>>ErbB signaling pathway;>>Ras signaling pathway;>>Rap1 signaling pathway;>>cAMP signaling pathway;>>Chemokine signaling pathway;>>HIF-1 signaling pathway;>>FoxO signaling pathway;>>Phosphatidylinositol signaling system;>>Sphingolipid signaling pathway;>>Phospholipase D signaling pathway;>>Autophagy - animal;>>mTOR signaling pathway;>>PI3K-Akt signaling pathway;>>AMPK signaling pathway;>>Apoptosis;>>Longevity regulating pathway;>>Longevity regulating pathway - multiple species;>>Cellular senescence;>>Axon guidance;>>VEGF signaling pathway;>>Osteoclast differentiation;>>Focal adhesion;>>Signaling pathways regulating pluripotency of stem cells;>>Platelet activation;>>Neutrophil extracellular trap formation;>>Toll-like receptor signaling pathway;>>C-type lectin receptor signaling pathway;>>JAK-STAT signaling pathway;>>Natural killer cell mediat

• Gene Name：
• PIK3CA

• Protein Name：
• 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha;5-bisphosphate 3-kinase catalytic subunit alpha isoform;caPI3K;CLOVE;CWS5;MCAP;MCM;MCMTC;MGC142161;MGC142163;p110 alpha;p110alpha;Phosphatidylin

• Human Gene Id：
• 5290

• Human Swiss Prot No：
• P42336

• Mouse Gene Id：
• 18706

• Mouse Swiss Prot No：
• P42337

• Rat Gene Id：
• 170911

• Immunogen：
• Synthesized peptide derived from human PIK3CA H1047R AA range: 1000-1068

• Specificity：
• The antibody can specifically recognize the h1047r mutation of human PIK3CA protein, and does not react with wild-type PIK3CA protein.

• Formulation：
• PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

• Source：
• Mouse, Monoclonal/IgG2b, kappa

• Dilution：
• IHC 1:50-200. ELISA 1:500-5000

• Purification：
• The antibody was affinity-purified from ascites by affinity-chromatography using specific immunogen.

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha;5-bisphosphate 3-kinase catalytic subunit alpha isoform;caPI3K;CLOVE;CWS5;MCAP;MCM;MCMTC;MGC142161;MGC142163;p110 alpha;p110alpha;Phosphatidylinositol 3 kinase catalytic alpha polypeptide;Phosphatidylinositol 3 kinase catalytic 110 KD alpha;Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha;Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform;Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha;Phosphatidylinositol-4;Phosphoinositide 3 kinase catalytic alpha polypeptide;PI 3 Kinase catalytic subunit alpha;PI3 kinase p110 subunit alpha;PI3-kinase subunit alpha;PI3K;PI3K-alpha;PI3KC A;PIK3C A;Pik3ca;PK3CA;PK3CA_HUMAN;PtdIns 3 kinase p110;PtdIns-3-kinase subunit alpha;PtdIns-3-kinase subunit p110-alpha;Serine/threonine protein kinase PIK3CA

• Molecular Weight(Da)：
• 124kD

• Observed Band(KD)：
• 124kD

• Background：
• Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016],

• Function：
• catalytic activity:ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.,disease:Defects in PIK3CA are associated with breast cancer [MIM:114480].,disease:Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].,disease:Defects in PIK3CA are associated with ovarian cancer [MIM:167000]. Ovarian cancer is the leading cause of death from gynecologic malignancy. It is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases. These typical features relate to the biology of the disease, which is a principal determinant of outcome.,disease:Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550].,disease:PI3KCA mutations affecting exons 9 and 20 display gender-and tissue-specific patterns, thus suggesting that the

• Subcellular Location：
• Cytoplasmic

• Expression：
• Gastric adenocarcinoma with PIK3CA H1047R protein expression

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs